Current Report Filing (8-k)
18 December 2021 - 09:16AM
Edgar (US Regulatory)
0001326190
false
0001326190
2021-12-17
2021-12-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
December 17, 2021
ALTIMMUNE,
INC.
(Exact name of registrant as specified in its
charter)
Delaware
|
|
001-32587
|
|
20-2726770
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
910 Clopper Road Suite 201S
Gaithersburg, Maryland
|
|
|
|
20878
|
(Address of principal executive offices)
|
|
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (240) 654-1450
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, par value $0.0001 per share
|
ALT
|
The NASDAQ Global Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
Item 1.02
|
Termination of a Material Definitive Agreement.
|
On December 17, 2021,
Altimmune, Inc. (the “Company”) terminated the Master Services Agreement with Lonza Houston Inc. (“Lonza”), dated
November 5, 2020 (the “MSA”), between the parties and the associated Statement of Work (the “SOW”), which SOW
was previously disclosed in a Current Report on Form 8-K filed on March 12, 2021.
The
SOW provided that Lonza would engineer, construct and qualify a dedicated manufacturing suite for the clinical and commercial supply of
the Company’s AdCOVID product candidate. The termination of the SOW and MSA is in connection with the Company’s previously
announced decision to discontinue its AdCOVID program, which was disclosed in a Current Report on Form 8-K, filed on June 29, 2021, and
incorporated by reference herein.
The foregoing description
of the SOW is a summary only and is qualified in its entirety by reference to the full text of the SOW, which is filed as Exhibit 10.2
to the Company’s quarterly report on Form 10-Q for the fiscal quarter ending March 31, 2021, and incorporated by reference herein.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 17, 2021
|
ALTIMMUNE, INC.
|
|
|
|
|
By:
|
/s/ William Brown
|
|
|
William Brown
|
|
|
Chief Financial Officer
|
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Mar 2023 to Mar 2024